Mathew Amaechi
In a significant breakthrough in the fight against malaria, the World Health Organization (WHO) has prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. This milestone marks a crucial step towards improving malaria care globally, particularly for patients with Plasmodium vivax (P. vivax) malaria.
The prequalified diagnostic test, known as the STANDARD G6PD System, enables healthcare providers to safely administer anti-relapse medications, such as tafenoquine products. This is especially crucial in regions where malaria is endemic, as it will help reduce the risk of acute haemolysis caused by G6PD deficiency.
According to Dr. Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, “The prequalification of this G6PD enzyme test can help countries enhance access to quality-assured tests, enabling safe and effective treatment and prevention of relapsing malaria”.
The WHO’s decision is a testament to its commitment to improving global health equity. By streamlining its processes for product recommendations and prequalification, the organization aims to reduce the time it takes to introduce life-saving tools in low- and lower-middle-income countries.
With over 500 million people worldwide affected by G6PD deficiency, the STANDARD G6PD System holds immense promise for improving malaria outcomes and expanding access to safe, effective treatments.
